A ACLINICAL STUDY TO EVALUATE THE INFLUENCE OF DEGARELIX ON PROSTATE VOLUME IN PATIENTS WITH PROSTATE CANCER UNDERGOING PROSTATE BRACHYTHERAPY WITH PERMANENT SEED IMPLANTATION

A ACLINICAL STUDY TO EVALUATE THE INFLUENCE OF DEGARELIX ON PROSTATE VOLUME IN PATIENTS WITH PROSTATE CANCER UNDERGOING PROSTATE BRACHYTHERAPY WITH PERMANENT SEED IMPLANTATION - A ACLINICAL STUDY TO EVALUATE THE INFLUENCE OF DEGARELIX ON PROSTATE VOLUME IN PATIENTS WITH PROSTATE CANCER UNDERGOING PROSTATE BRACHYTHERAPY WITH PERMANENT SEED IMPLANTATION

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015129

Enrollment

Registered

2014-09-12

Start date

2014-08-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

degarelix

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Adenocarcinoma of the prostate histologically confirmed. Prostate volume greater than 40cc and recommended to downsize the prostate to overcome an anatomical limitation of performing an implant. Stable medical condition, including the absence of severe hepatological, cardiac renal and hematological disorder etc

Exclusion criteria

Exclusion criteria: Uncontroled general complication. etc

Design outcomes

Primary

Measure	Time frame
prostate volume reduction rate	—

Countries

Japan

Contacts

Public ContactTakeo Kosaka

Keio University School of Medicine Department of Urology

moto-oya@z3.keio.jp03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026